[go: up one dir, main page]

WO2008102716A1 - Agent for treatment of adhd-related diseases - Google Patents

Agent for treatment of adhd-related diseases Download PDF

Info

Publication number
WO2008102716A1
WO2008102716A1 PCT/JP2008/052611 JP2008052611W WO2008102716A1 WO 2008102716 A1 WO2008102716 A1 WO 2008102716A1 JP 2008052611 W JP2008052611 W JP 2008052611W WO 2008102716 A1 WO2008102716 A1 WO 2008102716A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhd
agent
treatment
related diseases
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052611
Other languages
French (fr)
Japanese (ja)
Inventor
Chihiro Tohda
Masashi Yamada
Hiroto Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Publication of WO2008102716A1 publication Critical patent/WO2008102716A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Anesthesiology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)

Abstract

Disclosed is an agent for treatment of ADHD-related diseases, which contains a compound represented by the formula (1) below or at least one pharmaceutically acceptable salt thereof as an active ingredient. (1) (In the formula, R1 and R2 independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group; and R3 represents a hydrogen atom, a hydroxy group, an alkyl group, an alkoxy group or a sugar residue.)
PCT/JP2008/052611 2007-02-19 2008-02-18 Agent for treatment of adhd-related diseases Ceased WO2008102716A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007038498A JP2010100529A (en) 2007-02-19 2007-02-19 Adhd-related disease medicine
JP2007-038498 2007-02-19

Publications (1)

Publication Number Publication Date
WO2008102716A1 true WO2008102716A1 (en) 2008-08-28

Family

ID=39709993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052611 Ceased WO2008102716A1 (en) 2007-02-19 2008-02-18 Agent for treatment of adhd-related diseases

Country Status (2)

Country Link
JP (1) JP2010100529A (en)
WO (1) WO2008102716A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010364A1 (en) * 2009-07-21 2011-01-27 リードケミカル株式会社 Compound having neurite-outgrowing activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176428A (en) * 2004-12-22 2006-07-06 Toyama Univ Neural network restructuring agent and neural network restructuring method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176428A (en) * 2004-12-22 2006-07-06 Toyama Univ Neural network restructuring agent and neural network restructuring method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUBOYAMA T. ET AL.: "Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha", NEUROREPORT, vol. 13, no. 14, 2002, pages 1715 - 1720, XP003016643 *
TODA C.: "Overcoming several neurodegenerative diseases by axonal and synaptic formations - the development of therapeutic medicines and unraveling pathophysiologycal mechanisms -", BULLETIN OF THE JAPANES SOCIETY FOR NEUROCHEMISTRY, vol. 45, no. 4, 2006, pages 681 - 688 *
TOHDA C. ET AL.: "Scientific basis for the anti-dementia drugs of constituents from Ashwagandha (withania somnifera)", JOURNAL OF TRADITIONAL MEDICINES, vol. 22, no. SUPPL. 1, 2005, pages 176 - 182 *
ZHAO J. ET AL.: "Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities", CHEM. PHARM. BULL., vol. 50, no. 6, 2002, pages 760 - 765, XP003016642 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010364A1 (en) * 2009-07-21 2011-01-27 リードケミカル株式会社 Compound having neurite-outgrowing activity
US8841284B2 (en) 2009-07-21 2014-09-23 Lead Chemical Co., Ltd Compound having neurite-outgrowing activity

Also Published As

Publication number Publication date
JP2010100529A (en) 2010-05-06

Similar Documents

Publication Publication Date Title
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2009051119A1 (en) Pyrimidyl indoline compound
WO2009044788A1 (en) Benzoxazinone derivative
WO2009020140A1 (en) Adamantylurea derivative
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2008108323A1 (en) Drug for treatment of influenza
WO2008087933A1 (en) NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON IϰB KINASE β
TW200728307A (en) Novel spirochromanone derivatives
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
WO2007135527A3 (en) Benzimidazolyl compounds
UA97351C2 (en) Coumarin derivative having antitumor activity
WO2010066629A3 (en) Novel azaindoles
WO2008140099A1 (en) Tetrazoyloxime derivative and plant disease control agent
WO2008114812A1 (en) Jak inhibitor
MX2010001566A (en) Aminopyrazole amide derivative.
WO2006113552A3 (en) Cyanoarylamines
MX2009011076A (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient.
WO2006116733A3 (en) Protein kinase inhibitors
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
WO2008136377A1 (en) Bicyclic heterocyclic compound
WO2007017728A3 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711435

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711435

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP